The American Association for Cancer Research (AACR) 2020 Annual Meeting was held virtually, following a common trend in medical meetings this year. In early April 2020, due to the rapid escalation of the COVID-19 pandemic, the AACR Board of Directors made the decision not to move forward with an in-person Annual Meeting, and instead to present segments of the meeting program in two AACR Virtual Annual Meetings. The AACR Virtual Annual Meetings I and II took place April 27-28 and June 22- 24.

The meeting included preclinical and early clinical results from oncology drug candidates, but investigators also presented updated results from several key clinical trials. Included below is a summary from the meeting:

• Theratechnologies Inc. had the most AACR events added (9) to the Biomedtracker database over the course of the split meeting. BioInvent International and Surface Oncology were second with 4 events each.
• Similarly, Theratechnologies’ TH-1902, a conjugated peptide composed of docetaxel joined to Theratechnologies’ novel investigational peptide TH19P01 that targets Sortilin 1 (SORT1), had the most associated events with 5. ABTL0812, an oral small molecule that binds to the nuclear receptors PPARa and PPARg, and Optune, a tumor treatment field (TTField) device, each had 3 AACR events added to the database.
• The most prevalent indication among AACR events was Solid Tumors, followed by Cancer with 88 and 34 events, each; highlighting the early stage of many of the data releases.
• SORT1 and poly (ADP-ribose) polymerase (PARP) were the most common targets among AACR events. Cancer devices and the PD- 1/L1 and L2 receptor/ligand system were the next most discussed targets from the meeting with 4 events each.

Like our report? Have any questions or feedback? Please let us know at askanalyst@sagientresearch.com.
For our disclosures, please read the Biomedtracker Research Standards.